1pO:d) aX G [8&\}8u 6zJT]}&A$To 7rVZw ^ RtgsJ Hlf:;w8wI x{,Cl1CXm,ml On8# !}CmC!H!} O] b%s!8Ksj j$]: g]X_y[]FMg]yg_5q_gA J%?%f dI$K20d wvI^abYvZIY k]tT]XmA7uXAkk N75w`Be7/&e 0p/dpTi0 t+||n`||U. |]k ^`]-x-] Sc /Z% _^& ~Xv&k PkPJFX[X 7C /OSn kOJ5} pDx eGyRyn?y4 CG X+|a 0rLv4 g6(.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/4sLRmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.